Catalysts / ABOS
Upcoming FDA decisions and readouts we track for Acumen Pharmaceuticals, each with the filing that announced it.
FreeBioList tracks 1 upcoming catalyst for Acumen Pharmaceuticals (ABOS, listed on Nasdaq). It concerns Sabirnetug (ACU193) (Early Alzheimer's disease).
First on the list: the Phase 2 readout for Sabirnetug (ACU193) (Early Alzheimer's disease), guided by the company to Late 2026.
The row links to an SEC filing (8-K or 6-K). It has been verified by a person reading the filing itself, most recently on 07 Oct 2026. The methodology page explains each status.
Background reading: Clinical trial phases explained: Phase 1 to Phase 4.
| Company ▾ | Drug ▾ | Effect / indication | Next catalyst ▾ | Phase / type ▾ | Status ▾ | Source | Options |
|---|---|---|---|---|---|---|---|
| Acumen Pharmaceuticals ABOS · Nasdaq | Sabirnetug (ACU193) | Early Alzheimer's disease | Late 2026 company guidance |
Phase 2 readout | Verified | 8-K exhibit 99.1 ↗ | Yes |
FreeBioList